Trial Profile
A Randomized, Open-label, Multicenter, Two-arm, Phase III Study to Evaluate Efficacy and Quality of Life in Patients With Metastatic Hormone Receptor-positive HER2-negative Breast Cancer Receiving Ribociclib in Combination With Endocrine Therapy or Chemotherapy With or Without Bevacizumab in First Line
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary) ; Anastrozole; Bevacizumab; Capecitabine; Exemestane; Fulvestrant; Goserelin; Letrozole; Leuprorelin; Leuprorelin; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms RIBBIT
- Sponsors iOMEDICO AG
- 20 Dec 2021 Status changed from active, no longer recruiting to completed.
- 01 Dec 2021 Planned End Date changed from 30 Jun 2026 to 30 Nov 2022.
- 25 Mar 2021 Status changed from recruiting to active, no longer recruiting.